Marc De Meulemeester

Canakinumab for the treatment of acute flares in difficult‐to‐treat gouty arthritis: Results of a multicenter, phase II, dose‐ranging study

Alexander So, Marc De Meulemeester, A. Pikhlak et al. · Arthritis & Rheumatism · 2010 · 312 citations

Medicine, Pharmacology, Pharmacotherapy +17

Canakinumab reduces the risk of acute gouty arthritis flares during initiation of allopurinol treatment: results of a double-blind, randomised study

Naomi Schlesinger, Eduardo Mysler, Hsiao‐Yi Lin et al. · Annals of the Rheumatic Diseases · 2011 · 240 citations · Full text

Medicine, Clinical Sciences, Pharmacotherapy +17

Efficacy and Safety of Respiratory Syncytial Virus (RSV) Prefusion F Protein Vaccine (RSVPreF3 OA) in Older Adults Over 2 RSV Seasons

Michael G. Ison, Alberto Papi, Eugene Athan et al. · Clinical Infectious Diseases · 2024 · 162 citations · Full text

Veterinary Medicine, Immunology, Infectious Diseases +17

Canakinumab relieves symptoms of acute flares and improves health-related quality of life in patients with difficult-to-treat Gouty Arthritis by suppressing inflammation: results of a randomized, dose-ranging study

Naomi Schlesinger, Marc De Meulemeester, A. Pikhlak et al. · Arthritis Research & Therapy · 2011 · 136 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

Respiratory Syncytial Virus Prefusion F Protein Vaccine Is Efficacious in Older Adults With Underlying Medical Conditions

Robert G. Feldman, Raffaele Antonelli Incalzi, Katie Steenackers et al. · Clinical Infectious Diseases · 2023 · 52 citations · Full text

Veterinary Medicine, Geriatric Medicine, Infectious Diseases +17